CAR-T therapies

News

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

News

AstraZeneca's push into CAR-T therapies for cancer has continued with an agreement to take full control of C-CAR031 from Chinese partner AbelZeta.

News

Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.

News

The FDA could make it harder for developers of CAR-T therapies to bring them to market by requiring full randomised controlled trials.

News

Gilead's Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate anito-cel, which could launch next year.

News

AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.